Cartesian Therapeutics (RNAC) Non-Current Debt (2015 - 2026)
Cartesian Therapeutics (RNAC) posted quarterly Non-Current Debt of $13.8 million for Q2 2023, down 39.09% year-over-year from $22.6 million in Q2 2022, and down 15.04% quarter-over-quarter from $16.2 million in Q1 2023.
Cartesian Therapeutics (RNAC) Non-Current Debt (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported Non-Current Debt for 8 consecutive years, with $13.8 million the latest figure, recorded in Q2 2023.
- In Q2 2023, Non-Current Debt fell 39.09% year-over-year to $13.8 million; the TTM figure through Jun 2023 stood at $13.8 million (down 39.09% YoY), while the FY2022 annual figure was $17.8 million, down 9.59% from the prior year.
- Non-Current Debt declined to $13.8 million in Q2 2023 per RNAC's latest filing, from $16.2 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $25.0 million in Q1 2022 and bottomed at $6.4 million in Q2 2020.
- Historically, Non-Current Debt has averaged $20.0 million across 4 years, with a median of $21.3 million in 2021.
- Annual changes were most pronounced in 2021 — Non-Current Debt surged 255.57% — and 2023, when it plunged 39.09%.
- Cartesian Therapeutics' Non-Current Debt stood at $24.8 million in 2020, then retreated by 20.65% to $19.7 million in 2021, then declined by 9.59% to $17.8 million in 2022, then decreased by 22.48% to $13.8 million in 2023.
- Business Quant data shows RNAC's Non-Current Debt at $13.8 million in Q2 2023, $16.2 million in Q1 2023, and $17.8 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Cartesian Therapeutics | 265.54 Mn | 265.54 Mn | - | 52.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 52.85 Mn |
| Jun 30, 2023 | 13.79 Mn |
| Mar 31, 2023 | 16.23 Mn |
| Dec 31, 2022 | 17.79 Mn |
| Sep 30, 2022 | 20.22 Mn |
| Jun 30, 2022 | 22.63 Mn |
| Mar 31, 2022 | 25.04 Mn |
| Dec 31, 2021 | 19.67 Mn |
| Sep 30, 2021 | 21.30 Mn |
| Jun 30, 2021 | 22.93 Mn |
| Mar 31, 2021 | 24.55 Mn |
| Dec 31, 2020 | 24.79 Mn |
| Sep 30, 2020 | 24.59 Mn |
| Jun 30, 2020 | 6.45 Mn |
| Jun 30, 2018 | 21.21 Mn |
| Mar 31, 2018 | 21.13 Mn |
| Dec 31, 2017 | 21.04 Mn |
| Sep 30, 2017 | 20.95 Mn |
| Jun 30, 2017 | 5.73 Mn |
| Mar 31, 2017 | 6.87 Mn |